Detalhe da pesquisa
1.
The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.
BMC Cancer
; 20(1): 738, 2020 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32770960
2.
Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.
Int J Cancer
; 145(9): 2418-2426, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30873587
3.
EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.
Oncologist
; 23(10): 1127-1132, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29739898
4.
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.
Mol Ther
; 24(6): 1150-1158, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27039845
5.
Rad51C-ATXN7 fusion gene expression in colorectal tumors.
Mol Cancer
; 15(1): 47, 2016 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27296891
6.
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
Cancer
; 122(6): 875-83, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26709987
7.
Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer.
Cancer Immunol Res
; 12(6): 731-743, 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38572955
8.
Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient data.
Contemp Clin Trials
; 125: 107083, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36638911
9.
Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience.
J Clin Med
; 12(12)2023 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37373756
10.
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors.
Biomark Res
; 10(1): 39, 2022 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658948
11.
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.
Cancers (Basel)
; 14(16)2022 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36010982
12.
Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
Clin Lung Cancer
; 23(1): 72-81, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34782240
13.
The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods.
Methods
; 52(4): 281-6, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20888418
14.
MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers.
Sci Rep
; 11(1): 4420, 2021 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33627769
15.
Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis.
Cell Death Dis
; 12(4): 287, 2021 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33731677
16.
MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells.
Int J Cancer
; 127(2): 313-20, 2010 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19921694
17.
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.
Clin Cancer Res
; 25(15): 4691-4700, 2019 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30988079
18.
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
Clin Cancer Res
; 13(4): 1246-52, 2007 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17317836
19.
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.
Clin Lung Cancer
; 19(6): e893-e900, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30197259
20.
Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.
Mol Cell Biol
; 23(12): 4056-65, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12773551